"But do it quietly and don't disturb the grown-ups. I, and others on this board, prefer to care about the patients that you screwed".

Wasn't this a line from the Trovan trial in Nigeria.

And I only thought we had trolls and pessimists posting on these Pfizer sites. I am glad to see we have "judgemental elitists" too.

You don't know squat about me, so save your "Fire and Brimstone" judgemental "Mightier than thou" "How noble I am" sermons for Sunday.

Most of us "Cerebral Cripples" lost 70% of our 401K in Pfizer stock due to mismanagement of the company over the last 10 years. Not to stock trading.

And I know all the slogans and corporate mission statements too.

"The Watient is Waiting."

"Well the Pfizer stockholders are Waiting too."

Keep posting negative comments on how the stock will keep going under $10 per share.

"The stock is up...."

unfortunately, we don't operate on your level. You can't see beyond financial gain. It is the myopic mentality and malignant stupidity of room temperature IQ merchants such as yourself that is largely responsible for the decline of Pfizer. Understand one thing little boy; we don't give a crap about the stock price; nor do we care about the token existance or the opinions of a cerebral cripple. You stick to what you care about - money. But do it quietly and don't disturb the grown-ups. I, and others on this board, prefer to care about the patients that you screwed.

I think we have judged you well so no doubt, you will want the last word on this. You need it, don't you. Please, the floor is open. Astound us.

Keep looking in the rear view mirror at the last ten years.
I buy and sell based on today and tomorrow.

Keep posting the negative comments how its heading under $10...lol

The stock is up to 15$ and change. However, if you have the brains to use a stock tracker with a ten year view you will see that it has been falling since 2001 when it was around $40.

And the dividend per share, dismal. From 32 cents a share to eighteen in a year.

"The stock is up...."

imbecile

The stock is up 2.5% per cent over $15.40 per share. Keep posting the negative comments how its heading under $10.

"Submitted by Anonymous on Sat, 21/11/2009 - 03:16

It is on the up at the moment. When is the best time to bale out? The future doesn't look too good so not expecting it to rise much more before it crashes again. What are your thoughts?"

To answer the OP: Sat, 21-Nov-2009 would have been a good day to bail.

"Fat cats like him are getting massive share options at $15"

Actually board members tend to get options at heavily discounted rates to the current share price with short periods before they vest. Even then that hasn't always been enough to save them in the face of the ongoing decline in the stock value.

Dead cat bounce. A Wall Street term that refers to a small, brief recovery in the price of a declining stock.

You'll see PFE rise just before Kindler takes his bow and his package. Won't be long now. Fat cats like him are getting massive share options at $15 so when it rises and he bails out he'll make a friggin fortune. I feel sorry for Pfizer and Wyeth (and all the others) that get continually shafted as their benefits get cut. If it were me I think I'd be very disgruntled.

The stock is up 3 per cent over $15 per share. Keep posting the negative comments how its heading under $10.

Wyeth brings some additional revenue, but not enough to cover their massive overhead. I suspect that investors figured Pfizer would have some new products, but in this past year, there have been tons of phase III failures.

I think the stock will keep falling. Maybe some day, it will drop so low that someone else will buy Pfizer out!

--> I disagree. That is nonsense.

This is nonsense:

"The institutional investors, pension fund managers, equity fund brokers, mutual fund managers and banking conglomerates will not let the stock fall below $10 based on net holdings leverage and sheer volume of shares in their investor funds."

You don't think that as Pfizer's revenues decline due to the patent cliff that these people will bail??? Every drug you named has a ticking clock and NOTHING to replace it.

and this:

"Pfizer still retains the title to being number one in big pharma with revenues of $50 Billion dollars."

That's today. Look a few years out. "They" are. Dividend cut. No new revenues. Enjoy that title of #1 now... because in two years, it's gone. GONE.

Accupril-- Groton WRONG! WL
Aricept-- Groton WRONG! Eisai
Bextra-- Groton WRONG! Pharmacia
Caduet-- Groton WRONG--combination of Lipitor (WL) and Norvasc (Sandwich)
Camptosar-- Groton
Celobrex-- Groton WRONG! Pharmacia
Chantix-- Groton Yes, and look what it does to people...
Cefobid-- Groton
Depo Provera-- Groton
Difucan--Groton WRONG! Sandwich
Ellence--Groton WRONG--Pharmacia
Eraxis-- Groton --so how come it was origianlly LY303366?
Geodon--Groton

Groton guys trying to re-write history to make themselves look good?

OK this says it all. Time to bale out. Sell Pfizer shares as soon as possible and pocket the cash. It can only get worse...

Groton--Awwwww, rotten Groton where the sewer meets the sea

Accupril-- Groton
Aricept-- Groton
Bextra-- Groton
Caduet-- Groton
Camptosar-- Groton
Celobrex-- Groton
Chantix-- Groton
Cefobid-- Groton
Depo Provera-- Groton
Difucan--Groton
Ellence--Groton
Eraxis-- Groton
Geodon--Groton
Inspra--??
Lipitor--WL and about to go off patent
Lyrica--WL (just...) --doing OK (don't mention the weight gain...)
Macugen--Ok but niche?
Norvasc-Pfizer (Sandwich)--off patent
Neurontin--WL, off patent and subject of a lot of dodgy marketing
Relpax--WL??
Sezentry-(sic)--Pfizer (Sandwich) and makes no money
Sutent--Sugen--probably the most exciting drug on the list--even if it looks horrible!)
Tikosyn--dropped years ago!!(??)
Vfend--Pfizer--Sandwich?? How's this doing?
Viagra--Pfizer Sandwich--proof that marketing can beat better product profile (vardenafil is a much better drug)
Xalatan--?? makes any money?
Xanax--?? makes any money?
Zoloft--Pfizer groton--doing OK
Zyyvox (sic)--niche??

You infinite wisdom convinced me that this list of Pfizer products is worthless and there is nothing anything of value that Pfizer manufactures.

I bet you that that most companies would want the revenue of $50 Billion dollars generated from these worthless drugs.

"From A to Z such as accupril, aricept, Bextra, Caduet, Camptosar, Celobrex, Chantix, Cefobid, Depo Provera, Detrol, Difucan, Ellence, Eraxis, Geodon, Inspra, Lipitor, Lyrica, Macugen, Norvasc, Neurontin, Relpax, Sezentry, Sutent, Tikosyn, Vfend, Viagra, Xalatan, Xanax, Zoloft, Zyyvox"

Please correct if I'm wrong but...

Accupril--off patent (WL?)
Aricept--in licensed (Eisai?)
Bextra--Pharmacia (and not safe?)
Caduet--Pfizer! (off patent soon?) (sandwich?)
Camptosar--??
Celobrex--(sic) Pharmacia, probably safe
Chantix--Pfizer (Groton) and clearly NOT safe
Cefobid--??
Depo Provera--??
Detrol--does this make any money??
Difucan--(sic) Pfizer and off patent (actually a me-too off an AZ patent)--Sandwich
Ellence--??
Eraxis--??
Geodon--doing OK? Groton?
Inspra--??
Lipitor--WL and about to go off patent
Lyrica--WL (just...) --doing OK (don't mention the weight gain...)
Macugen--Ok but niche?
Norvasc-Pfizer (Sandwich)--off patent
Neurontin--WL, off patent and subject of a lot of dodgy marketing
Relpax--WL??
Sezentry-(sic)--Pfizer (Sandwich) and makes no money
Sutent--Sugen--probably the most exciting drug on the list--even if it looks horrible!)
Tikosyn--dropped years ago!!(??)
Vfend--Pfizer--Sandwich?? How's this doing?
Viagra--Pfizer Sandwich--proof that marketing can beat better product profile (vardenafil is a much better drug)
Xalatan--?? makes any money?
Xanax--?? makes any money?
Zoloft--Pfizer groton--doing OK
Zyyvox (sic)--niche??

I disagree. That is nonsense. Pfizer would need to file bankruptcy or lose their top five or six best selling drugs in order for that to happen.

If you have followed the stock for the past three years, the Lipitor patent cliff was accounted for in the share price correction when it dropped from $27 per share in July 2008 and fell to a low of $12.50 per share in February 2009.

It has been rising and falling between $12 and $20 range since then. A loss of value of 54%.

The institutional investors, pension fund managers, equity fund brokers, mutual fund managers and banking conglomerates will not let the stock fall below $10 based on net holdings leverage and sheer volume of shares in their investor funds.

Pfizer still retains the title to being number one in big pharma with revenues of $50 Billion dollars.

They have the best selling products.

From A to Z such as accupril, aricept, Bextra, Caduet, Camptosar, Celobrex, Chantix, Cefobid, Depo Provera, Detrol, Difucan, Ellence, Eraxis, Geodon, Inspra, Lipitor, Lyrica, Macugen, Norvasc, Neurontin, Relpax, Sezentry, Sutent, Tikosyn, Vfend, Viagra, Xalatan, Xanax, Zoloft, Zyyvox

This stock will see single digits before it sees $22. Patent cliff. Poor management. Dividend can only be cut. Full stop.

It is rated a buy, really.

I smell a short squeeze. Let me guess, someone is shorting PFE and has trouble covering. Pfizer is far from a sell and is definitely worth owning in this $15 range. The Street has revised from a buy to a hold and a day later they post a sell recommendation which basically states the Street can't call the pharmaceutical sector to save their life. I smell a rat. Don't let their bogus recommendations intimidate you. PFE is a solid company with multi-billion dollar revenues and will be worth over 22 by the end of the year. The average analyst has it as overweight which is going against the recommendation of most analysts.

Pfizer is moving up toward that magic number 15. I doubt it makes it there, down from 60 a few years ago, massive debt, no leadership, fried chicken research. No I think 13 is more likely.

I've got more idle cash than most of you PFE crooks and I'd rather take a big SHIT on my money in an open field and then burn it, as opposed to purchasing the POS PFE stock!

"The price target is $25 for the end of year leaving a potential return of 71%.

Pfizer share price has traditionally risen in 3Q. Weak tempered investors will be left out. UBS(UBS) and JPMorgan(JPM) predict that the shares will advance to $24. Credit Suisse (CS) says they will hit $22.

Pfizer's PEG ratio still ranks it as the cheapest Dow stock. It offers a yield of 4.9%, with a safe payout ratio of 61%."

Ok buddy let me help you out with a simple translation from our friends at JPM, UBS, CS and might as well throw the crooks of GS in there too; "We have a crapload of PFE inventory and we need to get the hell out". As a retail investor you are better served taking the opposite position of anything recommended by those crooks.

Comparing the Pfizer share price to that of other big pharma over the last ten years, Pfizer's has lost the most value (>65%). This despite the colossal revenue from Lipitor. Our path forward anyone?....

Buy, buy, buy! Buy it 'til your wallet implodes because we all know that JPM and all of the other investment banks are completely honest and never wrong in their predictions.

The price target is $25 for the end of year leaving a potential return of 71%.

Pfizer share price has traditionally risen in 3Q. Weak tempered investors will be left out. UBS(UBS) and JPMorgan(JPM) predict that the shares will advance to $24. Credit Suisse (CS) says they will hit $22.

Pfizer's PEG ratio still ranks it as the cheapest Dow stock. It offers a yield of 4.9%, with a safe payout ratio of 61%.

The dividend won't help PFE after the first of the year when taxes on dividends shoot up like a drug fiend on heroine. Dividend plays will be far less attractive and unfortunately there is only negative earnings growth here, so share price only erodes from this point. I am predicting single digit prices within the next year.

Share price slowly sinking...Expect to hear take over rumors soon.

Bull! complete nonsense. GW are a small UK based company who got lucky - a one drug company. They have just had a cannabis based spray approved for MS patients. Good for them. But of no market interest to Pfizer in any way.

??GWpharma??
pls rply

Probably just after they announce the purchase of a small if not tiny bio tech company GW?

"It trades at a price-to-projected-earnings ratio of 6.4"

Which is a valid statistic in most industries where earnings tend to steadily increase or decrease with the economy. The pharmaceutical industry is diferent because once your patent expires so do your earnings overnight. The PE ratio looks good at the minute precisely because some big products are about to drop off the patennt cliff. I don't think the numbers look nice at all.

What cracks me up is this idiot is touting the fact that Pfizer raised it's dividend from 16 cents to 18 cents. In 2008 the dividend was 32 cents and got cut 50% to 16 cents, so they're only giving the Shareholders back a tiny bit of what they recently took away. Big pfucking deal.

You want to know how your "Dogs of the DOW" strategy with this POS is going to work? Just look at a chart of PFE vs EK from about the mid 1990's to today because the PFE chart will emulate the EK chart very soon. That's what happens when a company is grossly mismanaged and backs themselves into a corner with no new products to bail them out.

<>

Exactly, those per share growth estimates are totally idiotic spewed forth by so called "experts" that have no understanding of simple mathematics, (see exponential growth). You can not grow a company of this size at the predicted growth rates. There are not enough block busters in the history of all man kind to increase the market cap of this POS stock. The share price will bleed at a rate equal to or greater than the dividend until they either stop the div, or drastically cut their expenditures, or miraculously develop a boat load of new drugs. I don't see the development of the boat load of new drugs any time soon...sorry.

Just lipstick on a pig, dude.
Pfizer has $17 billion of cash and $46 billion of debt, equal to a quick ratio of 1.2 and a debt-to-equity ratio of 0.5.

It trades at a price-to-projected-earnings ratio of 6.4 and a price-to-book ratio of 1.3, 46% and 67% discounts to peer averages.

Its PEG ratio, a measure of value relative to projected growth, of 0.2 reflects an 80% discount to estimated fair value.

The price target is $25, leaving a potential return of 71%. UBS(UBS) and JPMorgan(JPM) predict that the shares will advance another 64% to $24. Credit Suisse (CS) says they will hit $22.

Jake Lynch reports that undervalued blue chips currently offer the market's best bets. They are likely to drop less in a sell-off because of relative safety and rise higher in a rally because of relative value.

Pfizer's PEG ratio ranks it as the cheapest Dow stock. It offers a yield of 4.9%, with a safe payout ratio of 61%. It recently raised its quarterly dividend from 16 cents to 18 cents.

Pfizer has $17 billion of cash and $46 billion of debt, equal to a quick ratio of 1.2 and a debt-to-equity ratio of 0.5.

It trades at a price-to-projected-earnings ratio of 6.4 and a price-to-book ratio of 1.3, 46% and 67% discounts to peer averages.
Just lipstick on a pig . . .

Its PEG ratio, a measure of value relative to projected growth, of 0.2 reflects an 80% discount to estimated fair value.

The price target is $25, leaving a potential return of 71%. UBS(UBS) and JPMorgan(JPM) predict that the shares will advance another 64% to $24. Credit Suisse (CS) says they will hit $22.

Jake Lynch reports that undervalued blue chips currently offer the market's best bets. They are likely to drop less in a sell-off because of relative safety and rise higher in a rally because of relative value.

Pfizer's PEG ratio ranks it as the cheapest Dow stock. It offers a yield of 4.9%, with a safe payout ratio of 61%. It recently raised its quarterly dividend from 16 cents to 18 cents.

Pfizer has $17 billion of cash and $46 billion of debt, equal to a quick ratio of 1.2 and a debt-to-equity ratio of 0.5.

It trades at a price-to-projected-earnings ratio of 6.4 and a price-to-book ratio of 1.3, 46% and 67% discounts to peer averages.

Its PEG ratio, a measure of value relative to projected growth, of 0.2 reflects an 80% discount to estimated fair value.

The price target is $25, leaving a potential return of 71%. UBS(UBS) and JPMorgan(JPM) predict that the shares will advance another 64% to $24. Credit Suisse (CS) says they will hit $22.

Jake Lynch reports that undervalued blue chips currently offer the market's best bets. They are likely to drop less in a sell-off because of relative safety and rise higher in a rally because of relative value.

Pfizer's PEG ratio ranks it as the cheapest Dow stock. It offers a yield of 4.9%, with a safe payout ratio of 61%. It recently raised its quarterly dividend from 16 cents to 18 cents.

You obviously have no clue what you're talking about. Anyone who had the balls to speak up was promptly pfired in the next wave. All those meetings and GPM crap are jammed down everyones throat by MANAGEMENT. They'd have done a lot better had they left people alone to do their jobs and let the Supervisors decide if they're doing it well or not, rather than trying to measure performance with a lot of phony parameters, half of which are adherence to Corporate double talk (Leadership Values anyone?).

I know one guy who has had 11 Supervisors in 18 months thanks to constant restructuring. How the hell do you produce anything under conditions like that?

No contradictions (egregious or otherwise). Those who weren't pfired were supposed to be the productive ones. From what I see the majority have engaged in the silly games that have been introduced to replace serious developmental research. Sitting around for meetings for hours on end, sucking up to the useless management, spending weeks and months writing ridiculous performance management documents about people who are producing nothing.... I'm sorry, but you can't blame it all on the management. Time for a bit of honesty. You guys and gals haven't been doing the job you were paid to, and you didn't have the b*lls to say anything.

"You obviously have no idea how egregiously you just contradicted yourself."

You need some lessons in logic. He did not contradict himself. You must be a manager or a scientist.

"Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend"

Is that good?

Going down !

Pfizer's motto is: "If you're gray, you're GONE"

AND "If you're gray, making six figures, you're TOAST"

"Time to cull the new generation of drug discoverers who have failed to discover drugs and have brought the company to the brink of oblivion. Time to cull unproductive managers who have fired productive workers. "

You obviously have no idea how egregiously you just contradicted yourself. The blame falls squarely on the shoulders of Management for executing too many mergers too fast which totally disrupted the ability of the real Scientists to do their jobs thanks to never ending reorgs and lay offs. As for pfiring productive workers, that's about ALL they've done just to save a few bucks on salaries. Pfizer's motto is: "If you're gray, you're GONE"

It's all about time.
Time (I think) for the company's Directors to take a long hard look at what has been done over the last ten years. We are told that the acquisition strategy/process allowed the company to get rid of dead wood and to select the best and the brightest. But, the results speak for themselves. The people retained have failed to produce viable drugs to fill the pipeline. Maybe the wrong people have been retained? Maybe the company needed a few more journeymen and a few less flash executives? All of the chopping and changing has failed to deliver results and it's time for someone (perhaps more than one?) to take responsibility for this failure. Time to take stock and make decisions about the future.
My own opinion is that the company needs to contract rapidly to a sustainable size, from where it can grow if results justify. Time to go back to the old 'lean and mean' model of drug discovery, where personal advancement is dependent on success in the clinic. Time to cull the new generation of drug discoverers who have failed to discover drugs and have brought the company to the brink of oblivion. Time to cull unproductive managers who have fired productive workers. On the other hand, the Directors could sit back in their comfy chairs and allow the company to fail. Time for new Directors?

BOSTON (MarketWatch) -- Drug stocks moved lower in early action Thursday, with Pfizer Inc. being the sharpest decliner among the large caps on news that one of its late-stage drug candidates had run aground during clinical testing

How's that PFE stock doing Moron?

Yet another drug fails in clinical! LOL!